These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33865695)

  • 1. [Evaluation of the change in pneumococcal vaccination in 2018 in adults in the Community of Madrid].
    Beca Martínez MT; Morey Montalvo M; Santos Sanz S; Barrio Cortes J; Cañellas Llabrés S; Lasheras Carbajo MD
    Semergen; 2021; 47(4):240-247. PubMed ID: 33865695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antipneumococcal vaccination in Catalonian adults: Vaccine coverages and adequacy to distinct guideline recommendations].
    Ochoa-Gondar O; Vila-Córcoles Á; de Diego C; Satué E; Vila-Rovira A; Aragón M
    Aten Primaria; 2018 Nov; 50(9):553-559. PubMed ID: 29373143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pneumococcal disease in adults: Risk levels and vaccine recommendations].
    Vila-Córcoles A; Ochoa-Gondar O
    Aten Primaria; 2017 Feb; 49(2):111-117. PubMed ID: 27765456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumococcal vaccination patterns among persons aged 65 years or older in the United States: A retrospective database analysis.
    Yang X; Zhang D; Ou W
    Vaccine; 2018 Nov; 36(49):7574-7579. PubMed ID: 30391053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
    Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
    Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vaccination against community acquired pneumonia in adult patients. A position paper by Neumoexpertos en Prevención].
    Redondo E; Rivero I; Vargas DA; Mascarós E; Díaz-Maroto JL; Linares M; Valdepérez J; Gil A; Molina J; Jimeno I; Ocaña D; Martinón-Torres F;
    Semergen; 2016 Oct; 42(7):464-475. PubMed ID: 27641310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
    Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
    Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
    Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
    Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
    Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pneumococcal immunization on total and antigen-specific B cells in patients with severe chronic kidney disease.
    Gaultier GN; McCready W; Ulanova M
    BMC Immunol; 2019 Nov; 20(1):41. PubMed ID: 31718534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
    Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715
    [No Abstract]   [Full Text] [Related]  

  • 13. Pneumococcal vaccination in older adults in the era of childhood vaccination: Public health insights from a Norwegian statistical prediction study.
    Steens A; Vestrheim DF; de Blasio BF
    Epidemics; 2015 Jun; 11():24-31. PubMed ID: 25979279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults.
    Atwood M; Beausoleil L; Breton MC; Laferriere C; Sato R; Weycker D
    Can J Public Health; 2018 Dec; 109(5-6):756-768. PubMed ID: 29981104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
    Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
    Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.
    Kantsø B; Halkjær SI; Thomsen OØ; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Vaccine; 2015 Oct; 33(41):5464-5469. PubMed ID: 26275480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine?
    Metersky ML; Dransfield MT; Jackson LA
    Chest; 2010 Sep; 138(3):486-90. PubMed ID: 20576729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C;
    PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
    Jiang Y; Gauthier A; Keeping S; Carroll S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):913-27. PubMed ID: 25189087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.